戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 envelope glycoprotein gp120 are resistant to ibalizumab.
2 al to gp120 V5 may restore susceptibility to ibalizumab.
3 IV-1 variants with reduced susceptibility to ibalizumab.
4 , including 10 strains resistant to parental ibalizumab.
5 -neutralizing TGFBR2 extracellular domain to ibalizumab, a non-immunosuppressive CD4 antibody(12,13),
6                           Both maraviroc and ibalizumab are being studied for prevention of HIV-1 tra
7 3 in domain 2 were found to be important for ibalizumab binding, with E77 and S79 in domain 1 also co
8 cular, clones with reduced susceptibility to ibalizumab contained fewer potential asparagine-linked g
9              Thus, a characterization of the ibalizumab epitope was conducted in an attempt to gain i
10 n addition, an X-ray crystal structure of an ibalizumab Fab/CD4(D1-D4)/adnectin complex revealed an e
11                                              Ibalizumab (formerly TNX-355) is a first-in-class, monoc
12                          In clinical trials, ibalizumab has demonstrated anti-HIV-1 activity in patie
13 ein not only provide an appreciation for why ibalizumab has not had significant adverse immunological
14                 The postattachment inhibitor ibalizumab has shown antiviral activity in phase 1 and 2
15 a lack of data on combined use of injectable ibalizumab (IBA) and lenacapavir (LEN) with optimized ba
16                                 We evaluated Ibalizumab (IBA)-containing standardized optimized salva
17 pivirine [CAB/RPV] +/- lenacapavir [LEN] +/- ibalizumab [IBA]) with viremia (>=50 c/mL) at a Ryan Whi
18 hat combine the HIV-1 inhibitory activity of ibalizumab (iMab), a humanized mAb directed to domain 2
19 nd an additional individual at Week 24 after Ibalizumab initiation.
20                                              Ibalizumab is a humanized monoclonal antibody that binds
21                                              Ibalizumab is a humanized monoclonal antibody that binds
22 t by engineering an N-linked glycan into the ibalizumab light chain at a position spatially proximal
23 lls a void between the gp120 V5 loop and the ibalizumab light chain, perhaps causing steric hindrance
24               A 9-week phase Ib study adding ibalizumab monotherapy to failing drug regimens led to t
25           Functionally, viruses with reduced ibalizumab susceptibility also displayed high levels of
26     Individual env clones exhibiting reduced ibalizumab susceptibility contained multiple amino acid
27                             The reduction in ibalizumab susceptibility due to the loss of V5 PNGSs wa
28 s) in variable region 5 (V5) than did paired ibalizumab-susceptible clones.
29 iviral activity, safety, and tolerability of ibalizumab treatment.
30                             Indeed, one such ibalizumab variant neutralized 100% of 118 diverse HIV-1
31 mouse monoclonal antibody that competes with ibalizumab, was localized entirely within domain 2 on re
32 this void contributes to HIV-1 resistance to ibalizumab, we reasoned that 'refilling' it by engineeri
33       Viruses with reduced susceptibility to ibalizumab were found to exhibit reduced susceptibility